Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

See How to

Filter conferences

Next Generation Cardiovascular Drug Development Summit

Next Generation Cardiovascular Drug Development Summit


Date of beginning

Tuesday, 25 April 2023


3 days


Boston, Massachusetts


United States


Nina Podmore


This email address is being protected from spambots. You need JavaScript enabled to view it.


Are you up to date on the latest research and developments in novel biologics to enhance regenerative and precision cardiovascular therapeutics? Don't miss the Next Generation Cardiovascular Drug Development Summit, coming to Boston on April 25-27 as the only industry-focused meeting dedicated to leveraging novel cell and gene therapies using mRNA, CRISPR/Cas9 and iPSCs for cardiovascular disease. This inaugural summit will delve deep into the understanding of genetic components of cardiovascular disease, utilisation of imaging biomarkers, delivery of precise cardiac therapeutics, optimization of preclinical animal models, and overcoming off-target genome editing to mitigate against toxicity and long-term effects and unlock the potential of novel biologics. With 3 days of abundant insights into the latest breakthroughs and research and a faculty of world-class speakers pioneering the next wave of novel and precise cardiovascular therapeutics, this is biopharma's unmissable meeting for the expedition of treatment for cardiovascular disease patients. URLs:Brochure: Tickets:  Date and Time: On Tue, 25 Apr 2023 09:00 - Thu, 27 Apr 2023 16:00 Venue details: Hyatt Regency Boston, One Ave. de Lafayette, Boston, Massachusetts, 02111, United States Prices:Drug Developer - Conference Only: USD 2999.00,Academic and Research - Conference Only: USD 2599.00,Solution Provider - Conference Only: USD 3799.00 Speakers: Christopher O'Donnell, Global Head Cardiovascular and Metabolism Translational Medicine, Novartis Institutes of Biomedical Research, Denise Yates, Director, Biomarker Development, Cardiovascular and Imaging, Novartis Institutes of Biomedical Research, Eric Adler, Chief Scientific Officer, LEXEO Therapeutics, Haig Aghajanian, Co-founder and Vice President, Research, Capstan Therapeutics, Ibrahim Domian, Vice President - Development, BlueRock Therapeutics, Jeff Madwed, Executive Director, Juvenescence Limited, John Zuris, Director, Editing Technologies, Editas Medicine, Jonathan Plehn, Chief Medical Officer, Sardocor Corporation, Julie Phillips, Senior Scientist, BioCardia, Kiran Musunuru, Professor of Medicine, Perelman School of Medicine at the University of Pennsylvania, Lei Zhao, Senior Director, Immunology, Cardiovascular and Fibrosis Translational Early Development, Bristol Myers Squibb, Lior Zangi, Associate Professor of Medicine, Cardiology and Genetics and Genomic Sciences, Icahn Genomics Institute at Mount Sinai, Masahiro Murakami, Executive Director - Diabetes and Cardiovascular, Eli Lilly and Co., Nolan Townsend, Chief Executive Officer, LEXEO Therapeutics, Peter Altman, Chief Executive Officer, BioCardia, Pooja Agarwal, Head of Gene Therapy and Research, BioMarin Pharmaceutical Inc., Steven Lubitz, Director in Translational Medicine, Novartis Institutes of Biomedical Research, Takehiko Kaneko, Chief Medical Officer, Heartseed Inc, Tim Hoey, Chief Scientific Officer, Tenaya Therapeutics, Waheed Jamal, Vice President, Global Head of Cardiovascular and Metabolic Medicine, Boehringer Ingelheim